Claims for Patent: 7,470,687

Summary for Patent: 7,470,687

Title:	Aryl oximes
Abstract:	Aryl oxime derivatives of the formula (I), in which R.sup.1, R.sup.2, R.sup.3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS. ##STR00001##
Inventor(s):	Eggenweiler; Hans-Michael (Darmstadt, DE), Beier; Norbert (Reinheim, DE), Schelling; Pierre (Muhltal, DE), Wolf; Michael (Darmstadt, DE)
Assignee:	Merck Patent GmbH (Darmstadt, DE)
Application Number:	11/429,181
Patent Claims:	1. A method of preparing a pharmaceutical composition, which comprises combining a pharmaceutically acceptable excipient with at least one compound of the formula I: ##STR00046## in which: R.sup.1, R.sup.2 are each, independently of one another, H, OH, OR.sup.8, --SR.sup.8, --SOR.sup.8, --SO.sub.2R.sup.8 or Hal, or R.sup.1 and R.sup.2 together are alternatively --OCH.sub.2O-- or --OCH.sub.2CH.sub.2O--; R.sup.3 is H, A''R.sup.7, COA''R.sup.7, COOA''R.sup.7, CONH.sub.2, CONHA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7), CONR.sup.10Het, NH.sub.2, NHA''R.sup.7, N(A''R.sup.7)(A'''R.sup.7), NCOA''R.sup.7 or NCOOA''R.sup.7; B is an aromatic isocyclic or heterocyclic radical, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by R.sup.4, R.sup.5 and/or R.sup.6; X is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NA''R.sup.7, and 1-7 H atoms are optionally replaced by F and/or Cl; R.sup.4, R.sup.5, R.sup.6 are each, independently of one another, H, A''R.sup.7, OH, OA''R.sup.7, NO.sub.2, NH.sub.2, NHA''R.sup.7, N(A''R.sup.7)(A'''R.sup.7), NHCOA''R.sup.7, NHCOOA''R.sup.7, NHCONH.sub.2, NHCONHA''R.sup.7, NHCON(A''R.sup.7)(A'''R.sup.7), Hal, COOH, COOA''R.sup.7, CONH.sub.2, CONHA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7), ##STR00047## R.sup.7 is H, COOH, COOA, CONH.sub.2, CONHA, CONAA', NH.sub.2, NHA, NAA', NCOA, NCOOA, OH or OA; R.sup.8 is A, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms; R.sup.9 is alkyl having 1-10 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NMe, NEt and/or by --CH.dbd.CH-- groups, 1-7 H atoms are optionally replaced by F and/or Cl, and/or 1 H atom is optionally replaced by R.sup.7, Y is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms are optionally replaced by F and/or Cl; A, A' are each, independently of one another, aryl, Het, alkyl having 1-10 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms may be replaced by F and/or Cl, or A and A' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NR.sup.9, NCOR.sup.9 or NCOOR.sup.9; A'', A'''are each, independently of one another, a single bond, alkylene having 1-10 carbon atoms, alkenylene having 2-8 carbon atoms or cycloalkylene having 3-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms are optionally replaced by F and/or Cl, or A'', and A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NR.sup.9, NCOR.sup.9 or NCOOR.sup.9; aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, R.sup.11, OR.sup.10, N(R.sup.10).sub.2, NO.sub.2, CN, COOR.sup.10, CON(R.sup.10).sub.2, NR.sup.10COR.sup.10, NR.sup.10CON(R.sup.10).sub.2, NR.sup.10SO.sub.2A, COR.sup.10, SO.sub.2N(R.sup.10).sub.2, or S(O).sub.mR.sup.11; R.sup.10 is H or alkyl having 1-6 carbon atoms, R.sup.11 is alkyl having 1-6 carbon atoms, Het is a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N, O and/or S atoms, which is unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, R.sup.11, OR.sup.10, N(R.sup.10).sub.2, NO.sub.2, CN, COOR.sup.10, CON(R.sup.10).sub.2, NR.sup.10COR.sup.10, NR.sup.10CON(R.sup.10).sub.2, NR.sup.10SO.sub.2R.sup.11, COR.sup.10, SO.sub.2NR.sup.10 and/or S(O).sub.mR.sup.11, Hal is F, Cl, Br or I, and m is 0, 1 or 2; or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios. 2. A composition comprising: at least one compound of the formula I: ##STR00048## in which: R.sup.1, R.sup.2 are each, independently of one another, H, OH, OR.sup.8, --SR.sup.8, --SOR.sup.8, --SO.sub.2R.sup.8 or Hal, or R.sup.1 and R.sup.2 together are alternatively --OCH.sub.2O-- or --OCH.sub.2CH.sub.2O--; R.sup.3 is H, A''R.sup.7, COA''R.sup.7, COOA''R.sup.7, CONH.sub.2, CONHA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7), CONR.sup.10Het, NH.sub.2, NHA''R.sup.7, N(A''R.sup.7)(A'''R.sup.7), NCOA''R.sup.7 or NCOOA''R.sup.7; B is an aromatic isocyclic or heterocyclic radical, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by R.sup.4, R.sup.5 and/or R.sup.6; X is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NA''R.sup.7, and 1-7 H atoms are optionally replaced by F and/or Cl; R.sup.4, R.sup.5, R.sup.6 are each, independently of one another, H, A''R.sup.7, OH, OA''R.sup.7, NO.sub.2, NH.sub.2, NHA''R.sup.7, N(A''R.sup.7)(A'''R.sup.7), NHCOA''R.sup.7, NHCOOA''R.sup.7, NHCONH.sub.2, NHCONHA''R.sup.7, NHCON(A''R.sup.7)(A'''R.sup.7), Hal, COOH, COOA''R.sup.7, CONH.sub.2, CONHA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7), ##STR00049## R.sup.7 is H, COOH, COOA, CONH.sub.2, CONHA, CONAA', NH.sub.2, NHA, NAA', NCOA, NCOOA, OH or OA; R.sup.8 is A, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms; R.sup.9 is alkyl having 1-10 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NMe, NEt and/or by --CH.dbd.CH-- groups, 1-7 H atoms are optionally replaced by F and/or Cl, and/or 1 H atom is optionally replaced by R.sup.7, Y is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms are optionally replaced by F and/or Cl; A, A' are each, independently of one another, aryl, Het, alkyl having 1-10 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms may be replaced by F and/or Cl, or A and A' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NR.sup.9, NCOR.sup.9 or NCOOR.sup.9; A'', A'''are each, independently of one another, a single bond, alkylene having 1-10 carbon atoms, alkenylene having 2-8 carbon atoms or cycloalkylene having 3-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms are optionally replaced by F and/or Cl, or A'' and A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NR.sup.9, NCOR.sup.9 or NCOOR.sup.9; aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, R.sup.11, OR.sup.10, N(R.sup.10).sub.2, NO.sub.2, CN, COOR.sup.10, CON(R.sup.10).sub.2, NR.sup.10COR.sup.10, NR.sup.10CON(R.sup.10).sub.2, NR.sup.10SO.sub.2A, COR.sup.10, SO.sub.2N(R.sup.10).sub.2, or S(O).sub.mR.sup.11; R.sup.10 is H or alkyl having 1-6 carbon atoms, R.sup.11 is alkyl having 1-6 carbon atoms, Het is a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N, O and/or S atoms, which is unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, R.sup.11, OR.sup.10, N(R.sup.10).sub.2, NO.sub.2, CN, COOR.sup.10, CON(R.sup.10).sub.2, NR.sup.10COR.sup.10, NR.sup.10CON(R.sup.10).sub.2, NR.sup.10SO.sub.2R.sup.11, COR.sup.10, SO.sub.2NR.sup.10 and/or S(O).sub.mR.sup.11, Hal is F, Cl, Br or I, and m is 0, 1 or 2; or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such; and at least one further component selected from the group consisting of: (a) a leukotriene biosynthesis inhibitor; (b) a receptor antagonist for the leukotrienes LTB.sub.4, LTC.sub.4, LTD.sub.4 and LTE.sub.4; (c) a PDE IV inhibitor; (d) a 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist; (e) a dual inhibitor of 5-lipoxygenase (5-LO) and antagonist of platelet activating factor (PAF); (f) a leukotriene antagonist; (g) an antihistamine H.sub.1 receptor antagonist; (h) a gastroprotective H.sub.2 receptor antagonist; (i) an .alpha..sub.1- and .alpha..sub.2-adrenoreceptor agonist vasoconstrictor sympathomimetic agent; (k) an anticholinergic agent; (l) an .alpha..sub.1- to .alpha..sub.4-adrenoreceptor agonist; (m) theophylline or aminophylline; (n) sodium cromoglycate; (o) a muscarinic receptor (M1, M2 and M3) antagonist; (p) a COX-1 inhibitor or nitric oxide; (q) the COX-2 selective inhibitor rofecoxib; (r) an insulin-like growth factor type I (IGF-1) mimetic; (s) ciclesonide; (t) an inhalation glucocorticoid with reduced systemic side effects; (u) a tryptase inhibitor; (v) a platelet activating factor (PAF) antagonist; (w) a monoclonal antibody against endogenous inflammatory entities; (y) an antitumour necrosis factor agent; (z) leflunomide; (aa) a TCR peptide; (bb) an interleukin converting enzyme (ICE) inhibitor; (cc) an IMPDH inhibitor; (dd) an adhesion molecule inhibitor; (ee) a cathepsin; (ff) a MAP kinase inhibitor; (gg) a glucose 6-phosphate dehydrogenase inhibitor; (hh) a kinin B.sub.1 and B.sub.2 receptor antagonist; (ii) gold in the form of an aurothio group together with hydrophilic groups; (jj) an immunosuppressive agent selected from the group consisting of cyclosporine, azathioprine and methotrexate; (kk) an anti-gout agent selected from the group consisting of colchicines; (ll) allopurinol; (mm) probenecide, sulfinpyrazone or benzbromarone; (nn) vinblastine or vincristine; (oo) an agent for promoting growth hormone secretion; (pp) an inhibitor of matrix metalloproteases (MMPs) selected from the group consisting of stromelysins, collagenases, gelatinases, aggrecanase, collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) and stromelysin-3 (MMP-11); (qq) transforming growth factor (TGF.beta.); (rr) platelet-derived growth factor (PDGF); (ss) basic fibroblast growth factor (bFGF); (tt) granulocyte macrophage colony stimulating factor (GM-CSF); (uu) capsaicin; (vv) a tachykinin NK.sub.1 and NK.sub.3 receptor antagonist; (ww) an elastase inhibitor; and (xx) an adenosine A2a receptor agonist. 3. A kit comprising separate packs of: (a) a pharmaceutically effective amount of at least one compound of the formula I: ##STR00050## in which: R.sup.1, R.sup.2 are each, independently of one another, H, OH, OR.sup.8, --SR.sup.8, --SOR.sup.8, --SO.sub.2R.sup.8 or Hal, or R.sup.1 and R.sup.2 together are alternatively --OCH.sub.2O-- or --OCH.sub.2CH.sub.2O--; R.sup.3 is H, A''R.sup.7, COA''R.sup.7, COOA''R.sup.7, CONH.sub.2, CONHA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7), CONR.sup.10Het, NH.sub.2, NHA''R.sup.7, N(A''R.sup.7)(A'''R.sup.7), NCOA''R.sup.7 or NCOOA''R.sup.7; B is an aromatic isocyclic or heterocyclic radical, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by R.sup.4, R.sup.5 and/or R.sup.6; X is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NA''R.sup.7, and 1-7 H atoms are optionally replaced by F and/or Cl; R.sup.4, R.sup.5, R.sup.6 are each, independently of one another, H, A''R.sup.7, OH, OA''R.sup.7, NO.sub.2, NH.sub.2, NHA''R.sup.7, N(A''R.sup.7)(A'''R.sup.7), NHCOA''R.sup.7, NHCOOA''R.sup.7, NHCONH.sub.2, NHCONHA''R.sup.7, NHCON(A''R.sup.7)(A'''R.sup.7), Hal, COOH, COOA''R.sup.7, CONH.sub.2, CONHA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7), ##STR00051## R.sup.7 is H, COOH, COOA, CONH.sub.2, CONHA, CONAA', NH.sub.2, NHA, NAA', NCOA, NCOOA, OH or OA; R.sup.8 is A, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms; R.sup.9 is alkyl having 1-10 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NMe, NEt and/or by --CH.dbd.CH-- groups, 1-7 H atoms are optionally replaced by F and/or Cl, and/or 1 H atom is optionally replaced by R.sup.7, Y is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms are optionally replaced by F and/or Cl; A, A' are each, independently of one another, aryl, Het, alkyl having 1-10 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms may be replaced by F and/or Cl, or A and A' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NR.sup.9, NCOR.sup.9 or NCOOR.sup.9; A'', A''' are each, independently of one another, a single bond, alkylene having 1-10 carbon atoms, alkenylene having 2-8 carbon atoms or cycloalkylene having 3-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH or NR.sup.9 and/or 1-7 H atoms are optionally replaced by F and/or Cl, or A'' and A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH.sub.2 groups are optionally replaced by O, S, SO, SO.sub.2, NH, NR.sup.9, NCOR.sup.9 or NCOOR.sup.9; aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, R.sup.11, OR.sup.10, N(R.sup.10).sub.2, NO.sub.2, CN, COOR.sup.10, CON(R.sup.10).sub.2, NR.sup.10COR.sup.10, NR.sup.10CON(R.sup.10).sub.2, NR.sup.10SO.sub.2A, COR.sup.10, SO.sub.2N(R.sup.10).sub.2, or S(O).sub.mR.sup.11; R.sup.10 is H or alkyl having 1-6 carbon atoms, R.sup.11 is alkyl having 1-6 carbon atoms, Het is a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N, O and/or S atoms, which is unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, R.sup.11, OR.sup.10, N(R.sup.10).sub.2, NO.sub.2, CN, COOR.sup.10, CON(R.sup.10).sub.2, NR.sup.10COR.sup.10, NR.sup.10CON(R.sup.10).sub.2, NR.sup.10SO.sub.2R.sup.11, COR.sup.10, SO.sub.2NR.sup.10 and/or S(O).sub.mR.sup.11, Hal is F, Cl, Br or I, and m is 0, 1 or 2; or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such, and (b) a pharmaceutically effective amount of a different pharmaceutically active ingredient. 4. A kit according to claim 3, wherein the different pharmaceutically active ingredient is selected from the group consisting of: (a) a leukotriene biosynthesis inhibitor; (b) a receptor antagonist for the leukotrienes LTB.sub.4, LTC.sub.4, LTD.sub.4 and LTE.sub.4; (c) a PDE IV inhibitor; (d) a 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist; (e) a dual inhibitor of 5-lipoxygenase (5-LO) and antagonist of platelet activating factor (PAF); (f) a leukotriene antagonist; (g) an antihistamine H.sub.1 receptor antagonist; (h) a gastroprotective H.sub.2 receptor antagonist; (i) an .alpha..sub.1- and .alpha..sub.2-adrenoreceptor agonist vasoconstrictor sympathomimetic agent; (k) an anticholinergic agent; (l) an .alpha..sub.1- to .alpha..sub.4-adrenoreceptor agonist; (m) theophylline or aminophylline; (n) sodium cromoglycate; (o) a muscarinic receptor (M1, M2 and M3) antagonist; (p) a COX-1 inhibitor or nitric oxide; (q) the COX-2 selective inhibitor rofecoxib; (r) an insulin-like growth factor type I (IGF-1) mimetic; (s) ciclesonide; (t) an inhalation glucocorticoid with reduced systemic side effects; (u) a tryptase inhibitor; (v) a platelet activating factor (PAF) antagonist; (w) a monoclonal antibody against endogenous inflammatory entities; (y) an antitumour necrosis factor agent; (z) leflunomide; (aa) a TCR peptide; (bb) an interleukin converting enzyme (ICE) inhibitor; (cc) an IMPDH inhibitor; (dd) an adhesion molecule inhibitor; (ee) a cathepsin; (ff) a MAP kinase inhibitor; (gg) a glucose 6-phosphate dehydrogenase inhibitor; (hh) a kinin B.sub.1 and B.sub.2 receptor antagonist; (ii) gold in the form of an aurothio group together with hydrophilic groups; (jj) an immunosuppressive agent selected from the group consisting of cyclosporine, azathioprine and methotrexate; (kk) an anti-gout agent selected from the group consisting of colchicines; (ll) allopurinol; (mm) probenecide, sulfinpyrazone or benzbromarone; (nn) vinblastine or vincristine; (oo) an agent for promoting growth hormone secretion; (pp) an inhibitor of matrix metalloproteases (MMPs) selected from the group consisting of stromelysins, collagenases, gelatinases, aggrecanase, collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) and stromelysin-3 (MMP-11); (qq) transforming growth factor (TGF.beta.); (rr) platelet-derived growth factor (PDGF); (ss) basic fibroblast growth factor (bFGF); (tt) granulocyte macrophage colony stimulating factor (GM-CSF); (uu) capsaicin; (w) a tachykinin NK.sub.1 and NK.sub.3 receptor antagonist; (ww) an elastase inhibitor; and (xx) an adenosine A2a receptor agonist. 5. A method according to claim 1, wherein, in the compound of formula I: R.sup.1, R.sup.2 are each, independently of one another, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy or F. 6. A method according to claim 1, wherein, in the compound of formula I: R.sup.3 is H, A'R.sup.7, COA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7) or CO--NR.sup.10-Het. 7. A method according to claim 1, wherein, in the compound of formula I: X is methylene, ethylene, propylene or butylene. 8. A method according to claim 1, wherein, in the compound of formula I: B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NO.sub.2, NH.sub.2, NAA', ##STR00052## 9. A method according to claim 1, wherein, in the compound of formula I: R.sup.1, R.sup.2 are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, X is methylene, ethylene, propylene or butylene, R.sup.3 is H, A''R.sup.7, COA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7) or CO--NR.sup.10-Het, A'', A''' are each, independently of one another, a single bond or alkylene having 1-10 carbon atoms, in which one CH.sub.2 group is optionally replaced by NH or NR.sup.9, or A'', A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one CH.sub.2 group is optionally replaced by NH or NR.sup.9, B is phenyl which is unsubstituted or monosubstituted by OR.sup.10, NO.sub.2, ##STR00053## NH.sub.2 or NHCOOA''R.sup.7, or unsubstituted pyridyl or pyridyl N-oxide, R.sup.7 is H, COOH, NHA or NAA', R.sup.9 is alkyl having 1-6 carbon atoms, R.sup.10 is H or alkyl having 1-6 carbon atoms, A, A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F and/or Cl, and Het is a monocyclic saturated heterocyclic radical having 1 to 2 N atoms, which is optionally monosubstituted or disubstituted by alkyl having 1-6 carbon atoms. 10. A method according to claim 1, wherein, the compound of formula I is: a) 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, b) benzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, c) 4-hydroxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, d) pyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, e) 1-oxypyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, f) 4-methoxybenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, g) benzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin -1-yl]-2-oxoethyl}oxime, h) pyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, i) 1-oxypyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, j) 4-nitrobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, k) 4-aminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, l) 4-tert-butyloxycarbonylaminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, m) 2-{[4-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, n) 2-{[3-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, o) 2-{[4-({2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2- -oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, p) {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoetho- xyimino}-2-phenylacetic acid, q) 2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hoxyimino}-N-methyl-N-(1-methylpiperidin-4-yl)-2-phenylacetamide, r) 1-(4-methylpiperazin-1-yl)-2-phenylethane-1,2-dione 2-(O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-ox- oethyl}oxime, s) N-(2-dimethylaminoethyl)-2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4- H-pyridazin-1-yl]-2-oxoethoxyimino}-2-phenylacetamide, or t) 2-{[4-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}-2-(1H-tetrazol-5-yl)acetonitrile. 11. A composition according to claim 2, wherein, in the compound of formula I: R.sup.1, R.sup.2 are each, independently of one another, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy or F. 12. A composition according to claim 2, wherein, in the compound of formula I: R.sup.3 is H, A''R.sup.7, COA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7) or CO--NR.sup.10-Het. 13. A composition according to claim 2, wherein, in the compound of formula I: X is methylene, ethylene, propylene or butylene. 14. A composition according to claim 2, wherein, in the compound of formula I: B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NO.sub.2, NH.sub.2, NAA', ##STR00054## 15. A composition according to claim 2, wherein, in the compound of formula I: R.sup.1, R.sup.2 are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, X is methylene, ethylene, propylene or butylene, R.sup.3 is H, A''R.sup.7, COA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7) or CO--NR.sup.10-Het, A'', A''' are each, independently of one another, a single bond or alkylene having 1-10 carbon atoms, in which one CH.sub.2 group is optionally replaced by NH or NR.sup.9, or A'', A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one CH.sub.2 group is optionally replaced by NH or NR.sup.9, B is phenyl which is unsubstituted or monosubstituted by OR.sup.10, NO.sub.2, ##STR00055## NH.sub.2 or NHCOOA''R.sup.7, or unsubstituted pyridyl or pyridyl N-oxide, R.sup.7 is H, COOH, NHA or NAA', R.sup.9 is alkyl having 1-6 carbon atoms, R.sup.10 is H or alkyl having 1-6 carbon atoms, A, A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F and/or Cl, and Het is a monocyclic saturated heterocyclic radical having 1 to 2 N atoms, which is optionally monosubstituted or disubstituted by alkyl having 1-6 carbon atoms. 16. A composition according to claim 2, wherein, the compound of formula I is: a) 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, b) benzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, c) 4-hydroxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, d) pyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, e) 1-oxypyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, f) 4-methoxybenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, g) benzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin -1-yl]-2-oxoethyl}oxime, h) pyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, i) 1-oxypyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, j) 4-nitrobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, k) 4-aminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, l) 4-tert-butyloxycarbonylaminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, m) 2-{[4-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, n) 2-{[3-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, o) 2-{[4-({2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2- -oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, p) {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoetho- xyimino}-2-phenylacetic acid, q) 2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hoxyimino}-N-methyl-N-(1-methylpiperidin-4-yl)-2-phenylacetamide, r) 1-(4-methylpiperazin-1-yl)-2-phenylethane-1,2-dione 2-(O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-ox- oethyl}oxime, s) N-(2-dimethylaminoethyl)-2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4- H-pyridazin-1-yl]-2-oxoethoxyimino}-2-phenylacetamide, or t) 2-{[4-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}-2-(1H-tetrazal-5-yl)acetonitrile. 17. A kit according to claim 4, wherein, in the compound of formula I: R.sup.1, R.sup.2 are each, independently of one another, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy or F. 18. A kit according to claim 4, wherein, in the compound of formula I: R.sup.3 is H, A''R.sup.7, COA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7) or CO--NR.sup.10-Het. 19. A kit according to claim 4, wherein, in the compound of formula I: X is methylene, ethylene, propylene or butylene. 20. A kit according to claim 4, wherein, in the compound of formula I: B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NO.sub.2, NH.sub.2, NAA', ##STR00056## 21. A kit according to claim 4, wherein, in the compound of formula I: R.sup.1, R.sup.2 are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, X is methylene, ethylene, propylene or butylene, R.sup.3 is H, A''R.sup.7, COA''R.sup.7, CON(A''R.sup.7)(A'''R.sup.7) or CO--NR.sup.10-Het, A'', A''' are each, independently of one another, a single bond or alkylene having 1-10 carbon atoms, in which one CH.sub.2 group is optionally replaced by NH or NR.sup.9, or A'', A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one CH.sub.2 group is optionally replaced by NH or NR.sup.9, B is phenyl which is unsubstituted or monosubstituted by OR.sup.10, NO.sub.2, ##STR00057## NH.sub.2 or NHCOOA''R.sup.7, or unsubstituted pyridyl or pyridyl N-oxide, R.sup.7 is H, COOH, NHA or NAA', R.sup.9 is alkyl having 1-6 carbon atoms, R.sup.10 is H or alkyl having 1-6 carbon atoms, A, A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F and/or Cl, and Het is a monocyclic saturated heterocyclic radical having 1 to 2 N atoms, which is optionally monosubstituted or disubstituted by alkyl having 1-6 carbon atoms. 22. A kit according to claim 4, wherein, the compound of formula I is: a) 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, b) benzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, c) 4-hydroxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, d) pyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, e) 1-oxypyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hyl}oxime, f) 4-methoxybenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, g) benzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin -1-yl]-2-oxoethyl}oxime, h) pyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, i) 1-oxypyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, j) 4-nitrobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, k) 4-aminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, l) 4-tert-butyloxycarbonylaminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoe- thyl}oxime, m) 2-{[4-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, n) 2-{[3-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, o) 2-{[4-({2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2- -oxoethoxyimino}methyl)phenyl]hydrazono}malononitrile, p) {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoetho- xyimino}-2-phenylacetic acid, q) 2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoet- hoxyimino}-N-methyl-N-(1-methylpiperidin-4-yl)-2-phenylacetamide, r) 1-(4-methylpiperazin-1-yl)-2-phenylethane-1,2-dione 2-(O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-ox- oethyl}oxime, s) N-(2-dimethylaminoethyl)-2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4- H-pyridazin-1-yl]-2-oxoethoxyimino}-2-phenylacetamide, or t) 2-{[4-({2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-- oxoethoxyimino}methyl)phenyl]hydrazono}-2-(1 H-tetrazol-5-yl)acetonitrile.

Details for Patent 7,470,687

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2022-06-10